Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis

This Phase Ⅲ randomized, double-blind, active- and placebo-controlled trial aims to assess the efficacy and safety of Rupatifen Fumarate Capsules for seasonal allergic rhinitis. Eligible participants will be randomized to Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets (active comparator), or matching placebo. All treatments are administered once daily at a consistent time with a 24 ± 2-hour interval between doses for 2 consecutive weeks.

NCT Number	NCT07711262
Lead Sponsor	Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
Conditions	Seasonal Allergic Rhinitis
Enrollment	550 participants
Start Date	2026-07
Primary Completion	2027-10 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-17